RECENT NEWS

US-based digital pathology and artificial intelligence (AI) firm Paige has announced a collaboration with Microsoft to apply the power of AI to digital pathology images to develop and deliver a new generation of clinical applications and computational biomarkers to transform cancer diagnosis and patient care.

The North East Innovation Lab is celebrating a two-year milestone birthday and has expanded its work in accelerating the development of diagnostics for a range of virus and health threats.

Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies.

Qiagen has announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation.

The National Institutes of Health has awarded eight research grants in the USA, to refine new technologies for early diagnosis of severe illnesses resulting from SARS-CoV-2 infection in children.

European manufacturers of medical devices are set to get more time to prepare for forthcoming regulatory changes, after the European Commission adopted a proposal to delay the changes.

Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round. The new $36 million investment was led by Oppenheimer Holdings. The Series C funding brings the total amount raised since inception to circa $120 million.

Bruker Corporation has announced the acquisition of Acquifer Imaging GmbH, a pioneer in big-data management solutions for bioimaging and high-content microscopy.

Virax Biolabs has launched the distribution of human papillomavirus (HPV) test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union.

Bluestar Genomics has jointly announced the company’s commercialisation of its first test for early detection of pancreatic cancer in high-risk patients, and unveiled a new name, ClearNote Health.

UK registered SMEs can apply for a share of up to £25 million in grants to develop innovative solutions to health and healthcare challenges.

Heska Corporation, a global provider of advanced veterinary diagnostic and specialty products and solutions, has completed the previously announced acquisition of LightDeck Diagnostics, a pioneer in planar waveguide fluorescence immunoassay diagnostics.

A new online tech community has been launched by NHS Digital, aimed at supporting those working to integrate systems with national healthcare services.

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today applauded Congress for reaching an agreement on the Consolidated Appropriations Act of 2023 and recognising that it was not the appropriate mechanism for advancing the Verifying Accurate Leading-edge IVCT Development (VALID) Act.

Thermo Fisher Scientific has announced that it has completed its acquisition of The Binding Site Group, a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion.

'Vaccines As Tools To Combat Antimicrobial Resistance' is due to take place as an in-person meeting on 27–28 February 2023, at Edgbaston Park Hotel and Conference Centre in Birmingham, UK.

The Swedish medtech company Capitainer AB has announced that Professor Mathias Uhlén is investing in the company and joining the company’s advisory board. Mathias Uhlén is a world-leading scientist in biotechnology and proteomics and a successful serial entrepreneur.

SamanTree Medical has announced the publication of clinical data in prostate cancer, expanding the potential clinical utility of its proprietary medical imaging platform, the Histolog Scanner.

Health Education England’s Allied Health Professions Lead, Professor Beverley Harden, has been awarded an MBE in the New Year Honours list for services to healthcare.

ChromaDex, a global bioscience company dedicated to healthy ageing, announced promising new findings based on a previously published clinical trial of the company’s proprietary Niagen ingredient (patented nicotinamide riboside [NR]), which was supported by the ChromaDex External Research Program (CERP).